Hyloris Pharmaceuticals (FRA:52U) Margin of Safety % (DCF FCF Based) : N/A (As of Mar. 03, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Hyloris Pharmaceuticals Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Hyloris Pharmaceuticals's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Hyloris Pharmaceuticals's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Hyloris Pharmaceuticals's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hyloris Pharmaceuticals's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Hyloris Pharmaceuticals's Margin of Safety % (DCF FCF Based) falls into.

Hyloris Pharmaceuticals Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Hyloris Pharmaceuticals's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyloris Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyloris Pharmaceuticals SA (FRA:52U) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

0AB6:UK 52U:Germany HYL:Belgium

Address

Boulevard Patience et Beaujonc No. 3/1, Liege, BEL, 4000

Website

https://www.hyloris.com

Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain with various other products in the pipeline. Its revenue is mainly generated in the United States.

Hyloris Pharmaceuticals Headlines

No Headlines